DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Lirilumab is an investigational drug.
There have been 13 clinical trials for Lirilumab. The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2012.
The most common disease conditions in clinical trials are Neoplasms, Leukemia, and Leukemia, Myeloid. The leading clinical trial sponsors are Bristol-Myers Squibb, M.D. Anderson Cancer Center, and Innate Pharma.
There are fifteen US patents protecting this investigational drug and seventy-eight international patents.
Recent Clinical Trials for Lirilumab
|Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer||Bristol-Myers Squibb||Phase 1|
|Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer||PrECOG, LLC.||Phase 1|
|A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (ECHO-208)||Incyte Corporation||Phase 1/Phase 2|
Top disease conditions for Lirilumab
Top clinical trial sponsors for Lirilumab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Lirilumab||⤷ Sign up for a Free Trial||Methods and compositions for treating conditions associated with an abnormal inflammatory responses||First Wave Bio, Inc. (Ann Arbor, MI)||⤷ Sign up for a Free Trial|
|Lirilumab||⤷ Sign up for a Free Trial||Cholestosome vesicles for incorporation of molecules into chylomicrons||THERASYN SENSORS, INC. (Eggertsville, NY)||⤷ Sign up for a Free Trial|
|Lirilumab||⤷ Sign up for a Free Trial||LPT-723 and immune checkpoint inhibitor combinations and methods of treatment||BIOMED VALLEY DISCOVERIES, INC. (Kansas City, MO)||⤷ Sign up for a Free Trial|
|Lirilumab||⤷ Sign up for a Free Trial||Binding-triggered transcriptional switches and methods of use thereof||The Regents of the University of California (Oakland, CA)||⤷ Sign up for a Free Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Lirilumab||Australia||AU2016315852||2035-09-01||⤷ Sign up for a Free Trial|
|Lirilumab||Canada||CA2997136||2035-09-01||⤷ Sign up for a Free Trial|
|Lirilumab||Chile||CL2018000559||2035-09-01||⤷ Sign up for a Free Trial|
|Lirilumab||China||CN109562137||2035-09-01||⤷ Sign up for a Free Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|